Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5603/NMR.2015.0024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Eur J Nucl Med Mol Imaging
February 2024
Nuclear Medicine Unit, Department of Medicine - DIMED, University Hospital of Padova, Padua, Italy.
Article Synopsis
- Scientists are studying different types of imaging to see how well they can find and assess neuroblastoma in kids, especially comparing a method called mIBG with new PET scans.!
- They looked at 10 studies involving 181 patients and found that the PET scans could detect more tumors than the mIBG method in many cases.!
- Although PET scans seem to work better, doctors are still figuring out if this will really change how they treat patients in the future.!
Diagnostic Performance of I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma.
J Nucl Med
June 2022
Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
I-metaiodobenzylguanidine (MIBG) scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma, but with low sensitivity because of low spatial resolution. I-MIBG PET may be able to overcome this limitation and improve the staging of patients with (suspected) pheochromocytoma. We analyzed the sensitivity, specificity, and positive and negative predictive values of I-MIBG PET in 43 consecutive patients with suspected (recurrence of) pheochromocytoma using histopathologic ( = 25) and clinical validation ( = 18) as the standard of truth.
View Article and Find Full Text PDFNuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.
J Pers Med
April 2021
Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands.
Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis.
View Article and Find Full Text PDFI-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.
J Nucl Med
January 2021
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike I-MIBG, I-MIBG allows high-resolution PET. We evaluated I-MIBG PET/CT for its diagnostic performance as directly compared with paired I-MIBG scans.
View Article and Find Full Text PDFIdentification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.
PLoS One
June 2017
Pediatric Oncology and Hematology, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Neuroectodermal tumours are characterized by aberrant processing of disialogangliosides concomitant with high expression of GD2 or GD3 on cell surfaces. Antibodies targeting GD2 are already in clinical use for therapy of neuroblastoma, a solid tumour of early childhood. Here, we set out to identify peptides with high affinity to human disialoganglioside GD2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!